Plant Name: Desmodium gangeticum
Taxonomic Information:
Plant ID: NPO7804
Plant Latin Name: Desmodium gangeticum
Taxonomy Genus: Desmodium
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
670324
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Philippines; Indonesia; India; Malaysia; Vietnam; China; Laos; ThailandTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyGeographical Distribution:
Philippines; Indonesia; India; Malaysia; Vietnam; China; Laos; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR1B; HTR1D; TAAR1; HTR2B; HTR2A; HTR1A; HTR2C; HTR6; MTNR1B; MTNR1A; | |
| ALOX15; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1A2; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | MTNR1B | Melatonin receptor 1B | P49286 | CHEMBL1946 |
| Small molecule receptor (family A GPCR) | MTNR1A | Melatonin receptor 1A | P48039 | CHEMBL1945 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.784E-10 | 1.850E-07 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.581E-10 | 2.469E-07 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7, MTNR1A, MTNR1B, TAAR1 |
| BP | GO:0023052; signaling | GO:0007268; chemical synaptic transmission | 5.264E-10 | 4.245E-07 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, MTNR1B |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 6.661E-10 | 4.835E-07 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 1.212E-09 | 7.996E-07 | HTR1A, HTR1B, HTR7 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 3.028E-09 | 1.884E-06 | HTR2A, HTR2B, HTR2C |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 3.156E-09 | 1.909E-06 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7, MTNR1A, MTNR1B |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.949E-07 | 9.429E-05 | ALOX15, HTR2A, HTR2B, HTR2C, THPO |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 4.878E-07 | 2.168E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 4.878E-07 | 2.168E-04 | HTR2A, HTR2C |
| MF | GO:0060089; molecular transducer activity | GO:0008502; melatonin receptor activity | 1.463E-06 | 5.878E-04 | MTNR1A, MTNR1B |
| BP | GO:0032501; multicellular organismal process | GO:0014827; intestine smooth muscle contraction | 2.924E-06 | 1.117E-03 | HTR1D, HTR2B |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 4.224E-06 | 1.484E-03 | HTR2A, HTR2B, HTR2C |
| BP | GO:0050896; response to stimulus | GO:0071502; cellular response to temperature stimulus | 4.872E-06 | 1.658E-03 | HTR1B, HTR2B |
| BP | GO:0009987; cellular process | GO:0014062; regulation of serotonin secretion | 1.022E-05 | 3.180E-03 | HTR1A, HTR1B |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 2.673E-05 | 7.462E-03 | HTR1B, HTR2B |
| BP | GO:0023052; signaling | GO:0046883; regulation of hormone secretion | 3.020E-05 | 8.324E-03 | HTR1A, HTR2A, HTR2C, MTNR1B |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.582E-21 | 2.064E-17 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.582E-21 | 2.064E-17 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 5.688E-21 | 2.064E-17 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 1.963E-14 | 3.886E-11 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.035E-18 | 2.277E-17 | HTR6, MTNR1A, HTR7, MTNR1B, HTR1D, HTR1A, HTR2B, HTR1B, HTR2C, HTR2A, TAAR1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 7.631E-18 | 8.394E-17 | HTR6, HTR7, HTR1D, ALOX15, HTR1A, HTR2B, HTR1B, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.047E-07 | 7.678E-07 | HTR6, HTR7, HTR2B, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.805E-06 | 4.843E-05 | HTR6, HTR1D, HTR1A, HTR1B |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 2.427E-05 | 1.061E-04 | HTR1D, HTR1A, HTR1B |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.993E-05 | 1.255E-04 | HTR2B, HTR2C, HTR2A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.893E-05 | 1.061E-04 | HTR2B, HTR2C, HTR2A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.828E-04 | 5.026E-04 | CYP1A2, ALOX15 |
| 09150 Organismal Systems | 09159 Environmental adaptation | hsa04713 | Circadian entrainment | 1.958E-03 | 4.785E-03 | MTNR1A, MTNR1B |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.495E-03 | 7.690E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1A; HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HTR2C; MTNR1A; HTR1A; HTR1B; HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR2C; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MTNR1B; HTR1D; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| NA: NA | Episode | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR2B; HTR1A; HTR1D; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | MTNR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| NA: NA | Social phobia | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; HTR1A; HTR1B; HTR1D; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; HTR6; MTNR1A; HTR1A; HTR1B; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Circadian rhythm sleep disorder | G47.2 | MTNR1A; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| NA: NA | Addiction | NA | HTR2A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; MTNR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; HTR2A; HTR2C; HTR6; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | HTR1A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
